L-Asparaginase-induced Posterior Reversible Encephalopathy Syndrome during Acute Lymphoblastic Leukemia Treatment in Children

Abstract

l-Asparaginase is a critical component in the treatment of acute lymphoblastic leukemia in children. It is known to cause coagulation abnormalities, thrombosis and hemorrhage in the central nervous system in addition to vasculitis and hypersensitivity reactions. The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (PRES) associated with l-asparaginase treatment. We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after l-asparaginase therapy. MRI showed increased T₂ signal intensity predominant in the posterior regions of the brain suggestive of PRES. Two of our patients developed septic shock and deteriorated whereas one patient improved and recovered completely.

Key words

l-Asparaginase - PRES - leukemia - MRI - neurotoxicity

References

• 1 Antunes NL. Seizures in children with systemic cancer.  Pediatr Neurol. 2003;  28 190-193
• 2 Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.  AJNR Am J Neuroradiol. 2006;  27 2179-2190
• 3 Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity.  AJNR Am J Neuroradiol. 2001;  22 1901-1914
• 4 Bushara KO, Rust RS. Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin's lymphoma.  Pediatr Neurol. 1997;  17 185-187
• 5 Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?.  Stroke. 1994;  25 1215-1218
• 6 Chen CY, Zimmerman RA, Faro S, Bilaniuk LT, Chou TY, Molloy PT. Childhood leukemia: central nervous system abnormalities during and after treatment.  AJNR Am J Neuroradiol. 1996;  17 295-310
• 7 Chou MC, Lai PH, Yeh LR. et al . Posterior reversible encephalopathy syndrome: magnetic resonance imaging and diffusion-weighted imaging in 12 cases.  Kaohsiung J Med Sci. 2004;  20 381-388
• 8 Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy.  Neurology. 1997;  49 686-689
• 9 Duru F, Ertem U, Dagdemir A. et al . Coexistence of life threatening chemotherapy related leukoencephalopathy, saggital sinus thrombosis and multiple organ failure in a child with acute lymphoblastic leukemia: an unusual case with clinical recovery.  Leuk Lymphoma. 1997;  26 377-385
• 10 Ferraz-Filho JR, Rocha-Filho JA, Bichuette TF, Albuquerque RC de, Sanchez RA, Souza AS. Studying the evolution and the magnetic resonance findings of reversible posterior leukoencephalopathy in children.  Arq Neuropsiquiatr. 2006;  64 718-722
• 11 Fleischhack G, Solymosi L, Reiter A, Bender-Gotze C, Eberl W, Bode U. Imaging methods in diagnosis of cerebrovascular complications with l-asparaginase therapy.  Klin Padiatr. 1994;  206 334-341
• 12 Gugliotta L, Mazzucconi MG, Leone G. et al . Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving l-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.  Eur J Haematol. 1992;  49 63-66
• 13 Hinchey J, Chaves C, Appignani B. et al . A reversible posterior leukoencephalopathy syndrome.  N Engl J Med. 1996;  334 494-500
• 14 Ito Y, Arahata Y, Goto Y. et al . Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.  AJNR Am J Neuroradiol. 1998;  19 415-417
• 15 Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Bohles H. Cerebrovascular complications of l-asparaginase in the therapy of acute lymphoblastic leukemia.  J Pediatr Hematol Oncol. 2003;  25 484-487
• 16 Kinoshita T, Moritani T, Shrier DA. et al . Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay.  Clin Imaging. 2003;  27 307-315
• 17 Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to l-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.  Leukemia. 1998;  12 660-665
• 18 Lee JH, Kim SW, Sung Kim J. Sagittal sinus thrombosis associated with transient free protein S deficiency after l-asparaginase treatment: case report and review of the literature.  Clin Neurol Neurosurg. 2000;  102 33-36
• 19 Morris EB, Laningham FH, Sandlund JT, Khan RB. Posterior reversible encephalopathy syndrome in children with cancer.  Pediatr Blood Cancer. 2007;  48 152-159
• 20 Nakasu Y, Nakasu S, Morikawa S, Uemura S, Inubushi T, Handa J. Diffusion-weighted MR in experimental sustained seizures elicited with kainic acid.  AJNR Am J Neuroradiol. 1995;  16 1185-1192
• 21 Narbone MC, Musolino R, Granata F, Mazzu I, Abbate M, Ferlazzo E. PRES: posterior or potentially reversible encephalopathy syndrome?.  Neurol Sci. 2006;  27 187-189
• 22 Nomura K, Ohno R, Hamaguchi K, Hata T, Hatanaka H, Matsuyama H. Clinicopathological report of cisplatin encephalopathy.  Rinsho Shinkeigaku. 1995;  35 64-69
• 23 Norman JK, Parke JT, Wilson DA, MacNall-Knapp RY. Reversible posterior leukoencephalopathy syndrome in children undergoing induction therapy for acute lymphoblastic leukemia.  Pediatr Blood Cancer. 2007;  49 198-203
• 24 Nowak-Gottl U, Kuhn N, Wolff JE. et al . Inhibition of hypercoagulation by antithrombin substitution in E. coli l-asparaginase-treated children.  Eur J Haematol. 1996;  56 35-38
• 25 Ohnuma T, Holland JF, Freeman A, Sinks LF. Biochemical and pharmacological studies with asparaginase in man.  Cancer Res. 1970;  30 2297-2305
• 26 Osborn A, Blaser S, Salzman K. Diagnostic Imaging: Brain. first edn. Saunders, Philadelphia 2004
• 27 Rangi PS, Partridge WJ, Newlands ES, Waldman AD. Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.  Neuroradiology. 2005;  47 586-590
• 28 Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK. l-Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.  Pediatr Neurosurg. 2002;  37 203-205
• 29 Rogers LR. Cerebrovascular complications in cancer patients.  Neurol Clin. 2003;  21 167-192
• 30 Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children.  Pediatr Neurol. 2001;  24 145-148
• 31 Schwartz RB, Bravo SM, Klufas RA. et al . Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases.  AJR Am J Roentgenol. 1995;  165 627-631
• 32 Shin RK, Stern JW, Janss AJ, Hunter JV, Liu GT. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia.  Neurology. 2001;  56 388-391
• 33 Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases.  Am J Obstet Gynecol. 1990;  163 1049-1054 , ; discussion 1054-1055
• 34 Suminoe A, Matsuzaki A, Kira R. et al . Reversible posterior leukoencephalopathy syndrome in children with cancers.  J Pediatr Hematol Oncol. 2003;  25 236-239
• 35 Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA. High-dose cytarabine neurotoxicity: MR findings during the acute phase.  AJNR Am J Neuroradiol. 1993;  14 1014-1016

Correspondence